Lucid Diagnostics CEO to Participate in Cantor Global Healthcare Conference Fireside Chat

Lucid Diagnostics Inc. announced that CEO Lishan Aklog will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 5, 2025, at 8:35 AM EDT. The live and archived webcast can be accessed on the company's website. Aklog's participation in the conference is expected to provide insight into Lucid's cancer prevention medical diagnostics business.

Lucid Diagnostics Inc. (NASDAQ: LUCD), a commercial-stage cancer prevention medical diagnostics company, has announced that its Chairman and CEO, Lishan Aklog, M.D., will participate in a fireside chat at the Cantor Global Healthcare Conference 2025. The event is scheduled to take place on September 5, 2025, at 8:35 AM EDT in New York. The live and archived webcast will be available on the company's website [1].

The fireside chat, which is expected to last for 30 minutes, will provide attendees with an opportunity to gain insights into Lucid's business operations, particularly its focus on cancer prevention through medical diagnostics. The company's flagship product, the EsoGuard® Esophageal DNA Test, is designed to detect esophageal precancer in patients with GERD, also known as chronic heartburn.

The Cantor Global Healthcare Conference 2025 is an annual event that brings together industry leaders, investors, and healthcare professionals to discuss the latest advancements and innovations in healthcare. Aklog's participation is expected to provide valuable insights into the company's strategic direction, market position, and future prospects.

Lucid Diagnostics has been actively involved in investor conferences and events, with recent appearances including the 2023 Cantor Fitzgerald Global Healthcare Conference and the presentation of positive data from its first prospective clinical utility study of the EsoGuard® test [2].

The company's recent financial performance has shown promising signs, with Lucid processing 2,756 EsoGuard® tests and recognizing $1.2 million in revenue during the second quarter of 2025 [3]. Additionally, the company has secured a meeting with the Centers for Medicare and Medicaid Services (CMS) to discuss the Medicare Local Coverage Determination (LCD) for the EsoGuard® test, which is scheduled for September 4, 2025 [4].

References:
[1] https://www.stocktitan.net/news/LUCD/lucid-diagnostics-to-participate-in-the-cantor-global-healthcare-9029pd9u73t4.html
[2] https://www.barchart.com/stocks/quotes/LUCD
[3] https://www.marketscreener.com/news/lucid-diagnostics-to-participate-in-the-cantor-global-healthcare-conference-2025-ce7c50dedc88f626